Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix hexa schedule comparison in Indian infants
2012-002426-70Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by GSK. Primary endpoints: Vaccine response to pertussis antigens and Antibody response to poliovirus types 1, 2, and 3.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2012-002426-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002426-70.